Details of the Metabolic Reaction (MR)

General Information of This Metabolic Reaction (MR) (ID: MR002214)
Formula
CYP3A4 ...
SVG example
Reactant Ruxolitinib M16 metabolite Product Ruxolitinib metabolite M9
Reactant Info Product Info
Metabolic Enzyme Cytochrome P450 3A4 (CYP3A4) DME Info
Cytochrome P450 2C9 (CYP2C9) DME Info
Other MR(s) Related to The Reactant of This MR
Other MR(s) That Produce The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR002027 Phenprocoumon 8-hydroxy-R-phenprocoumon Oxidation - 8-Hydroxylation Phenprocoumon [1]
MR008879 Ruxolitinib Ruxolitinib M16 metabolite Oxidation - 3-hydroxylation Ruxolitinib [2], [3]
MR002215 Ruxolitinib phosphate Ruxolitinib M16 metabolite Oxidation - 3-Hydroxylation Ruxolitinib phosphate [2]
References
1 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
2 Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans Drug Metab Dispos. 2010 Nov;38(11):2023-31. doi: 10.1124/dmd.110.033787.
3 The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.